Opaleye Management Inc.
- SEC CIK
- 0001595855
- Latest filing
- Aug 14, 2026
Holdings in Q4 2023
Holdings as of Dec 31, 2023, filed Feb 14, 2024. Long positions only; changes compare share counts with Q3 2023.
- Positions
- 46
- +6 vs. Q3 2023
- Portfolio value
- $372.5M
- +$68.1M (+22.4%) vs. Q3 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| HROWHarrow, Inc. | COM | 3,820,000 | $42.8M | 11.5% | +25,000+0.7% | Added | History |
| TGTXTG Therapeutics, Inc. | COM | 2,215,000 | $37.8M | 10.2% | +325,000+17.2% | Added | History |
| SLRNACELYRIN, Inc. | COM | 4,146,138 | $30.9M | 8.3% | 00.0% | Unchanged | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 610,000 | $28.0M | 7.5% | −43,000−6.6% | Reduced | History |
| OCULOcular Therapeutix, Inc | COM | 6,070,000 | $27.1M | 7.3% | −398,000−6.2% | Reduced | History |
| CPRXCatalyst Pharmaceuticals, Inc. | COM | 1,257,200 | $21.4M | 5.8% | +52,200+4.3% | Added | History |
| KROSKeros Therapeutics, Inc. | COM | 357,500 | $14.2M | 3.8% | −2,900−0.8% | Reduced | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 311,500 | $11.1M | 3.0% | 00.0% | Unchanged | History |
| ETONEton Pharmaceuticals, Inc. | COM | 2,529,887 | $11.1M | 3.0% | +99,617+4.1% | Added | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 307,500 | $10.9M | 2.9% | −62,500−16.9% | Reduced | History |
| ARVNArvinas, Inc. | COM | 263,700 | $10.9M | 2.9% | +263,700 | New | History |
| CDXSCodexis, Inc. | COM | 3,045,525 | $9.29M | 2.5% | +1,926,625+172.2% | Added | History |
| BHVNBiohaven Ltd. | COM | 200,000 | $8.56M | 2.3% | −239,000−54.4% | Reduced | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 699,000 | $7.65M | 2.1% | −176,405−20.2% | Reduced | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 897,000 | $7.29M | 2.0% | +287,000+47.0% | Added | History |
| ARQTArcutis Biotherapeutics, Inc. | COM | 1,960,000 | $6.33M | 1.7% | +1,960,000 | New | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 308,500 | $6.25M | 1.7% | 00.0% | Unchanged | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 563,500 | $6.13M | 1.6% | −20,500−3.5% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 90,000 | $5.65M | 1.5% | 00.0% | Unchanged | History |
| LQDALiquidia Corp | COM NEW | 445,000 | $5.35M | 1.4% | −125,700−22.0% | Reduced | History |
| TARAProtara Therapeutics, Inc. | COM STK | 2,692,594 | $5.05M | 1.4% | 00.0% | Unchanged | History |
| URGNUroGen Pharma Ltd. | COM | 320,000 | $4.80M | 1.3% | 00.0% | Unchanged | History |
| XOMAXOMA Royalty Corp | COM NEW | 250,000 | $4.63M | 1.2% | −24,500−8.9% | Reduced | History |
| APLTApplied Therapeutics, Inc. | COM | 1,092,500 | $3.66M | 1.0% | +199,500+22.3% | Added | History |
| RLMDRelmada Therapeutics, Inc. | COM | 877,000 | $3.63M | 1.0% | +847,000+2,823.3% | Added | History |
| TRVITrevi Therapeutics, Inc. | COM | 2,535,000 | $3.40M | 0.9% | +829,100+48.6% | Added | History |
| JSPRJasper Therapeutics, Inc. | COM | 3,985,340 | $3.14M | 0.8% | +3,985,340 | New | History |
| NTLAIntellia Therapeutics, Inc. | COM | 99,000 | $3.02M | 0.8% | +99,000 | New | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 265,388 | $2.96M | 0.8% | +265,388 | New | History |
| Gossamer Bio, Inc.38341PAA0 | NOTE 5.000% 6/0 | – | $2.92M | 0.8% | – | – | – |
| LRMRLarimar Therapeutics, Inc. | COM | 623,500 | $2.84M | 0.8% | −225,000−26.5% | Reduced | History |
| VTYXVentyx Biosciences, Inc. | COM | 1,140,000 | $2.82M | 0.8% | +1,140,000 | New | History |
| SYRSSyros Pharmaceuticals, Inc. | COM NEW | 359,370 | $2.80M | 0.8% | +359,370 | New | History |
| GOSSGossamer Bio, Inc. | COM | 2,982,200 | $2.72M | 0.7% | −1,772,000−37.3% | Reduced | History |
| PTGXProtagonist Therapeutics, Inc | COM | 112,700 | $2.58M | 0.7% | +112,700 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 150,000 | $1.84M | 0.5% | −350,000−70.0% | Reduced | History |
| VSTMVerastem, Inc. | COM NEW | 211,400 | $1.72M | 0.5% | 00.0% | Unchanged | History |
| NYXHNyxoah SA | COMMONSTOCK | 344,800 | $1.60M | 0.4% | −97,096−22.0% | Reduced | History |
| Morphosys AG617760202 | SPONSORED ADS | 145,000 | $1.44M | 0.4% | −1,064,380−88.0% | Reduced | – |
| PGENPrecigen, Inc. | COM | 1,012,500 | $1.36M | 0.4% | +84,000+9.0% | Added | History |
| STROSutro Biopharma, Inc. | COM | 301,491 | $1.29M | 0.3% | +301,491 | New | History |
| CNTXContext Therapeutics Inc. | COM | 975,000 | $1.10M | 0.3% | +975,000 | New | History |
| FULCFulcrum Therapeutics, Inc. | COM | 130,000 | $877.5K | 0.2% | +130,000 | New | History |
| ALGSAligos Therapeutics, Inc. | COM | 1,297,000 | $861.2K | 0.2% | +1,297,000 | New | History |
| KNSAKiniksa Pharmaceuticals International, plc | COM CL A | 37,500 | $640.2K | 0.2% | +37,500 | New | History |
| BDSXBiodesix Inc | COM | 496,500 | – | – | +40,927+9.0% | Added | History |
Sold out since Q3 2023 (7)
Positions held at the end of Q3 2023 that are gone from this filing.
| Security | Class | Shares in Q3 2023 | Value in Q3 2023 | % of portfolio in Q3 2023 | History |
|---|---|---|---|---|---|
| TELATELA Bio, Inc. | COM | 750,000 | $6.00M | 2.0% | History |
| GERNGeron Corp | COM | 1,915,000 | $4.06M | 1.3% | History |
| IGMSIGM Biosciences, Inc. | COM | 261,000 | $2.18M | 0.7% | History |
| TCONTracon Pharmaceuticals, Inc. | COM NEW | 4,764,508 | $848.1K | 0.3% | History |
| XERSXeris Biopharma Holdings, Inc. | COM | 390,000 | $725.4K | 0.2% | History |
| FBIOFortress Biotech, Inc. | COM | 2,000,000 | $580.6K | 0.2% | History |
| KZRKezar Life Sciences, Inc. | COM | 425,000 | $505.8K | 0.2% | History |